Clinical Trial Development: RA’s Role, OEWG, and IRB Submissions Martha Heckel Protocol Associate, ACRIN Dept. of Protocol Development & Regulatory.

Slides:



Advertisements
Similar presentations
1 WORKSHOP 4: KEY COMMENTS FROM THE PANEL DISCUSSION The 3rd Kitasato University - Harvard School of Public Health Symposium Wednesday October 2nd - Thursday.
Advertisements

Guideline for Monitoring of Clinical Trials for Cooperative Groups, CCOP Research Bases, and the Clinical Trials Support Unit (CTSU) Lore Lagrone Program.
 The National Cancer Institute (NCI) is:  The largest of the Institutes that constitute the National Institutes of Health  The largest sponsor of research.
POST APPROVAL MONITORING AND EDUCATION PROGRAM Jane Lehmbeck 1, Sarah Blackman 1, Karen Davenport 2, Karen Parks 1 Office of the Vice President for Research.
Genius online Appraisal Management System 1. Appraiser Configuration Getting Started Appraisal Management let the user to effectively conduct a users.
Clinical Trials with SARC We’re here to help.. What can SARC do for you? Provide help developing a research idea Provide help with contacting pharma Provide.
Tracking Protocol Development Timelines Steve Friedman, MHSA Chief, Clinical Trials Operations and Informatics Branch.
THE HR APPRENTICERICHMOND THE HR APPRENTICE RICHMOND Marvelous Membership Mavericks.
Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate.
2011 ACRIN Annual Meeting ACRIN ACCELERATED ACCRUAL DEMONSTRATION PROJECT Department of Radiology The University of Iowa Carol Mertens, Ph.D., CFLE, LMHC.
Role of the Oncology Research Team Carmen B. Jacobs, RN, OCN, CCRP.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
2011 ACRIN Annual Meeting The ACRIN Accrual Project at University of Washington Constance Lehman, MD. PhD David Mankoff, MD. PhD Tiffany Wong, MS.
CTEP Protocol and Information Office (PIO) Overview.
RESIDENT PROJECTS ROBERT LEONHARD QUALITY IMPROVEMENT MANAGER.
1 Local Readiness Team Lead Kick-Off Meeting May 16, 2007.
OEWG Kick-Off Meeting Meg Mooney, MD Chief, Clinical Investigations Branch CTEP, DCTD, NCI – March 24, 2010 CTEP & Cooperative Group Plans for OEWG Implementation:
Project Charters Module 3
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
Overview of the RBS Plan Review Process Leslie Ann Hay, Implementation Lead Megan Stout, CDSS Analyst.
Evaluation Plan Steven Clauser, PhD Chief, Outcomes Research Branch Applied Research Program Division of Cancer Control and Population Sciences NCCCP Launch.
CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch
AccrualNet: A New NCI Tool for Supporting Accrual to Clinical Trials Linda Parreco, RN, MS NCI, Office of Communication and Education September 29, 2010.
ACRIN CV Committee ACRIN PDRC ACRIN PA 4008 Protocol and Regulatory Requirements Patricia Atkinson, Quality Control Monitor.
1 MARCH 2012 Regulatory Documents & the CTSU.
Rural & Regional Water Business Expenditure Review Briefing for Businesses 4 October 2005.
HRPP METRICS Cynthia Monahan, MBA, CIP IRB Director Boston University Charles River Campus IRB.
Rare Diseases Clinical Research Network Data Management and Coordinating Center (RDCRN DMCC) Rosalie Holland LDN Investigator Meeting at WORLDSymposium.
1 SAE Centralized Report and Review Process April 2012.
Preparing for Title IIA Monitoring Review (FY15) November 9, 2015 Deborah Walker Meagan Steiner David LeBlanc.
Good Clinical Practice (GCP) and Monitoring Practices
Project Management.
Implementing SMS in Civil Aviation: the Canadian Perspective
New project request process training
What are the characteristics of effective healthcare teams?
CONDUCTING THE TRIAL AT
MAINTAINING THE INVESTIGATOR’S SITE FILE
IRB reporting updates.
MTN-025 Study Specific Training
Reportable Events & Other IRB Updates February 2017
Board Standards and School Board Self-Assessment
Internship orientation: Research module basics
QUALITY IMPROVEMENT FINAL QUARTERLY COLLABORATIVE WORKSHOP
POC Procedures Working Group (POC-PWG) Work package 3 (As Built)
The Student Teaching Handbook
Part C State Performance Plan/Annual Performance Report:
Approaches to Implementing CPT in Your Organization
Standards Development: An Overview
Curricular Practical Training
Top Ten eIRB Application Mistakes
Webinar: ESSA Improvement Planning Requirements
Single Subject Protocol Modification
Myeloma UK Clinical Trial Network (CTN)
Understanding the Planned Changes to the Federal Policy on Protection of Human Subjects (the Common Rule) Megan Kasimatis Singleton, JD, MBE, CIP Assistant.
Get CLUed into VICTR Services and Support
The Student Teaching Handbook
Participant Retention
MAINTAINING THE INVESTIGATOR’S STUDY FILE
Expedited Status Update January 14, 2019
Manage Meetings.
Data & Learning Team February 1, 2018.
The Process for Final Approval: Ongoing Monitoring
Roles and Responsibilities
Clinical Trial Development: NRG Processes and NCI Requirements
PEARLS Overview and Research Team Management
Project Overview.
Clinical Trial Development: NRG Processes and NCI Requirements
Sepsis Program Development
New Special Education Teacher Webinar Series
Project Name Here Kick-off Date
Presentation transcript:

Clinical Trial Development: RA’s Role, OEWG, and IRB Submissions Martha Heckel Protocol Associate, ACRIN Dept. of Protocol Development & Regulatory Compliance

Overview of Discussion Points The RA in Trial Development Introducing the OEWG Timeline Trial Activation and Ramp-Up Phase

During Trial Development 1. The RA in Trial Development: Consider Role of RA Committee Rep Review of Protocol Contents Anticipate Obstacles to Avoid Protocol Violations Ponder: What Tools Would Help Trial Process?

RA Committee Rep’s Role Trial assigned to a representative from the RA Committee RA Committee rep attends t-cons during trial development

RA Committee Rep’s Role We’re looking for your input. Need another good reason to join the RA Committee? Get involved in early trial development to offer your thoughts!

During Trial Development In reviewing the protocol, keep in mind: Language for clarity Reasonable timelines for procedures Identifying pitfalls (obstacles to study compliance) Thus, avoiding Protocol Violations

During Trial Development Representative reviews the protocol from data collection/operations perspective: How well are the procedures defined? Is the protocol consistent? What might be confusing to an RA (missing details)?

During Trial Development How Can ACRIN Help You? Help the Trial? During trial development, chime in with ideas to assist the site RAs: Eligibility flip charts Patient handouts What else?

During Trial Development “I have ideas! Whom do I speak with?” ACRIN’s Project Managers and Communications team leads the development of recruitment and other study-related materials. Call Nancy Fredericks to get started!

During Trial Development Trial Development Is an Ongoing Process The conduct of the trial is important! We hope you will join our Site t-con calls. Contact us any time if you have specific feedback— see trends within a specific trial or across ACRIN trials.

Introduction to OEWG 2. Introducing the OEWG Timeline: What is the OEWG? What is this about a timeline? How will it impact ACRIN and sites?

OEWG … What? What is the OEWG? OEWG = Operational Efficiency Working Group Established in 2008, the OEWG has assessed how the cooperative groups function … and suggested changes.

OEWG Timeline What is this about a timeline? The OEWG and CTEP have implemented revised timelines for concept development through actual trial activation. Trial activation is defined as one site ready to accrue participants.

OEWG Timelines: Target The OEWG guidelines include hard drop-dead dates depending on the phase of the treatment trial. Phase I = 210 Days* Phase II = 210 Days* Phase III = 300 Days* * Without Timeouts; Absolute Deadlines are 18 (phases I and II) and 24 months (phase III).

OEWG Timelines: Timeouts Time-clock stops for issues outside of NCI’s or PI’s purview (i.e., pharma approval, IRB review). Timeout time is NOT counted towards Target Milestones; however, it IS counted toward the Absolute Deadline.

OEWG Timelines: Phases I and II Target Milestones

OEWG Timelines: Phase III Target Milestones

OEWG Timelines: Impact General impact on trial development: Trial design must be more complete prior to LOI or Concept submission; LOI or Concept has 60 or 90 days to be approved (depending on phase); Protocol must be submitted within 60 to 90 days (depending on phase); ...

OEWG Timelines: Impact AND … Forms and ancillary documents must be completed prior to activation. Which is another time point when RA Committee members come in—deadlines for forms feedback may be compressed for adherence to the OEWG Timeline Milestones.

OEWG and ACRIN While CTEP is introducing the OEWG timeline for TREATMENT trials only, at this time, ACRIN will adhere to the same timelines. ACRIN will always have to work within OEWG structure for cooperative trials with other groups (e.g., GOG or RTOG).

After Trial Activation TRIAL ACTIVATES!

Submitting to Local IRBs 3. Trial Activation and Ramp-Up Phase Once the initial protocol is approved, ACRIN requests for local IRB submission no more than 30 days from receipt … maybe less depending on OEWG timeline! For amendments, ACRIN allows 60 days for protocol approval.

Submitting to Local IRBs “Why the push? Don’t we have 60 to 90 days for approval?” Yes, technically … But amendments are often in response to site feedback to eliminate accrual barriers or provide clarification. So, the sooner, the better!

ACRIN trials would not be successful without our dedicated RAs. Thank You ACRIN trials would not be successful without our dedicated RAs. Thank you all for your commitment to ACRIN trials and the people who participate. We couldn’t do it without YOU!

Questions? 9 April 2019